Vistin Pharma is a Norwegian pharmaceutical company producing Metformin Hydrochloride (API). Our Metformin is also available as Direct Compressible lubricated granules and Solide Dosage Forms. As a solely dedicated European Metformin producer, we are a well positioned supplier to leading pharmaceutical companies. Our strategy is to significantly expand together with both current and new customers. With long pharmaceutical industry experience, we have built significant capacity and expertise as an API provider. Vistin Pharma has highly qualified employees and a dedicated manufacturing facility in Kragerø, Norway. The facility is certified according to current Good Manufacturing Practice (cGMP) and successfully inspected by the US Food and Drug Administration (FDA). Please visit Our Website www.vistin.com for additional information
View Top Employees from Vistin Pharma ASWebsite | http://www.vistin.com/ |
Ticker | VISTIN |
Revenue | $22 million |
Employees | 51 (39 on RocketReach) |
Founded | 2015 |
Address | 27 Oestensjoeveien, Oslo 0661, NO |
Phone | (473) 598-4200 |
Technologies | |
Industry | Pharmaceutical Manufacturing, Manufacturing General, Active pharmaceutical Ingredients (API), Manufacturing, CMO, Metformin, Manufacture of solid dosage forms, Opoids, Codeine Phosphate & Pholcodine |
Web Rank | 18 Million |
Keywords | Pharma Company Presentation Pdf, Vistin Pharma |
Competitors | Cambridge Major Laboratories Europe, ChemWerth Inc., Euticals, Sanochemia Pharmazeutika, Scientific Protein Labs LLC |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Vistin Pharma AS employee's phone or email?
The Vistin Pharma AS annual revenue was $22 million in 2024.
Vegard Heggem is the Vice President Operations of Vistin Pharma AS.
39 people are employed at Vistin Pharma AS.
The NAICS codes for Vistin Pharma AS are [3254, 32541, 325, 32].
The SIC codes for Vistin Pharma AS are [28, 283].